2006-2007年安徽省大肠埃希菌与肺炎克雷伯菌耐药性监测研究  

Changes in Antimicrobial Resistance among Clinical Isolates of Escherichia coli and Klebsiella pneumoniae in Anhui Province 2006-2007

作　　者：郜玉峰[1] 李家斌[1,2] 

机构地区：[1]安徽医科大学第一附属医院感染病科,安徽合肥230022 [2]安徽省细菌耐药中心,安徽合肥230022

出　　处：《中华医院感染学杂志》2009年第12期1586-1589,共4页Chinese Journal of Nosocomiology

基　　金：国家自然科学基金项目(30772286);安徽省自然科学基金项目(070413110)

摘　　要：目的了解临床分离大肠埃希菌与肺炎克雷伯菌对抗菌药物耐药性变迁情况。方法对2006-2007年安徽省30所医院的细菌耐药监测资料中大肠埃希菌和肺炎克雷伯菌临床分离株的耐药性变迁情况进行分析,细菌药敏采用琼脂稀释法;并按2007年美国临床实验室标准化研究所(CLSI)指导原则的标准,计算细菌对抗菌药物的耐药率、中介率和敏感率,采用SPSS11.5软件进行统计分析。结果头孢吡肟、头孢他啶、哌拉西林/他唑巴坦、阿米卡星对其有很好的抗菌活性;大肠埃希菌与肺炎克雷伯菌对头孢呋辛、头孢曲松、头孢噻肟、氨曲南及喹诺酮类药物仍有较高的耐药率;2006、2007年大肠埃希菌产ESBLs株检出率分别为48.9%、47.2%,肺炎克雷伯菌产ESBLs株检出率为36.6%、40.0%。结论碳青酶烯类抗菌药物对大肠埃希菌和肺炎克雷伯菌(含产ESBLs菌)保持最高敏感性和较强的抗菌活性,而对加酶抑制剂β-内酰胺类抗菌药物的耐药率逐年升高。OBJECTIVE To investigate the trend of resistance to antimicrobial agents among clinical isolates of Escherichia coli and Klebsiella pneumoniae in 2006--2007. METHODS Agar diffusion test was used to analyze the changes in drug susceptibility of E. coli and K. pneumoniae from 30 hospitals in Anhui in 2006-- 2007. The resistant rate, intermediate rate and susceptibility rate of drugs were calculated according to the criteria in guidelines of CLSI （2007）. RESULTS Carbapenems were the most active antimicrobial agents tested against E. coli and K. pneumoniae. Cefepime, ceftazidime, piperacillin/tazobactam and amikacin showed excellent activity against E. coli and K. pneumoniae. E. coli and K. pneurnoniae were still resistant to cefuroxime, ceftriaxone, cefotaxime and aztreonam. ESBLs-producing E. coli strains accounted for 48. 9% in the year of 2006 and for 47.2% in the year of 2007. ESBLs-producing K. pneumoniae strains accounted for 36.6% in the year of 2006 and for 40.0M in the year of 2007. CONCLUSIONS Imipenem remains highly active against E. coli and K. pneumoniae.

关 键 词：大肠埃希菌 肺炎克雷伯菌 药物敏感试验 细菌耐药监测 

分 类 号：R378.21[医药卫生—病原生物学]